Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Buy" from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have received a consensus rating of "Buy" from the eight brokerages that are covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $32.29.

Several research firms recently issued reports on DAWN. The Goldman Sachs Group decreased their price target on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday, March 25th. Needham & Company LLC reiterated a "buy" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright restated a "buy" rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday. Bank of America lowered their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Finally, Wedbush reissued an "outperform" rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN traded down $0.49 during trading on Wednesday, reaching $7.22. The company had a trading volume of 934,681 shares, compared to its average volume of 1,101,994. Day One Biopharmaceuticals has a 52 week low of $7.06 and a 52 week high of $18.07. The business's 50 day moving average price is $10.13 and its 200-day moving average price is $12.38. The stock has a market cap of $731.78 million, a PE ratio of -7.01 and a beta of -1.24.

Remove Ads

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The business had revenue of $29.21 million during the quarter, compared to analysts' expectations of $27.11 million. Equities analysts anticipate that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Insider Activity

In other news, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. The trade was a 10.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $52,265.20. Following the sale, the chief financial officer now directly owns 252,638 shares of the company's stock, valued at approximately $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,064 shares of company stock valued at $251,925 in the last quarter. Company insiders own 8.40% of the company's stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $27,000. R Squared Ltd acquired a new position in Day One Biopharmaceuticals during the 4th quarter worth approximately $31,000. Tower Research Capital LLC TRC grew its stake in shares of Day One Biopharmaceuticals by 911.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock worth $135,000 after acquiring an additional 9,603 shares in the last quarter. E Fund Management Co. Ltd. bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth approximately $143,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $150,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.